News & Updates
Filter by Specialty:

MET amplification a predictor of response to crizotinib
A subanalysis of the ongoing phase II PROFILE 1001 study suggests that MET amplification may serve as one of the predictive biomarkers for response to crizotinib among patients with non-small-cell lung cancer (NSCLC).
MET amplification a predictor of response to crizotinib
12 Oct 2021
Pseudopyloric metaplasia does not predict development of gastric cancer
Neither gastric cancer nor gastric dysplasia is seen in patients with corpus atrophic gastritis (CAG) characterized at baseline with corpus pseudopyloric metaplasia (PPM) without corpus intestinal metaplasia (IM) because such lesions are consistently associated with corpus IM, reports a study.
Pseudopyloric metaplasia does not predict development of gastric cancer
10 Oct 2021
Targeted therapy superior to chemotherapy, best supportive care at improving survival in NSCLC
Survival benefit in patients with de novo stage IV nonsmall-cell lung cancer (NSCLC) depends on the type of treatment received, with significantly better median overall survival (OS) seen with the use of small-molecule targeted therapy against epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements than with best supportive care, reports a study.
Targeted therapy superior to chemotherapy, best supportive care at improving survival in NSCLC
09 Oct 2021
Neurovascular bundle sparing boosts postoperative sexual function in prostate cancer patients
The width of the spared neurovascular bundle (NVB) is an important indicator of postoperative sexual function after robot-assisted laparoscopic prostatectomy for prostate cancer, a recent study has found. These findings point to NVB as an easy intraoperative marker for assessing postoperative outcomes.